RhumbLine Advisers
SCNI

RhumbLine Advisers’s Scinai Immunotherapeutics SCNI Stock Holding History

RhumbLine Advisers’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.04K Hold
1,878
– – ﹤0.01% 3975
2025
Q4 		$1.33K Sell
1,878
-1,675
-47% -$1.91K ﹤0.01% 4014
2025
Q3 		$4.49K Buy
3,553
+70
+2% +$122 ﹤0.01% 3922
2025
Q2 		$7.97K Buy
3,483
+1,916
+122% +$4.82K ﹤0.01% 3890
2025
Q1 		$4.17K Sell
1,567
-86
-5% -$295 ﹤0.01% 3927
2024
Q4 		$5.5K Hold
1,653
– – ﹤0.01% 3940
2024
Q3 		$5.85K Buy
1,653
+515
+45% +$1.97K ﹤0.01% 3959
2024
Q2 		$3.24K Buy
1,138
+473
+71% +$1.96K ﹤0.01% 4148
2024
Q1 		$3.44K Buy
665
+134
+25% +$691 ﹤0.01% 4031
2023
Q4 		$3.08K Buy
531
+176
+50% +$1.21K ﹤0.01% 4050
2023
Q3 		$3.08K Buy
355
+5
+1% +$64 ﹤0.01% 4060
2023
Q2 		$4.76K Buy
+350
New +$6.04K ﹤0.01% 4097

Other funds holding SCNI

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RhumbLine Advisers's SCNI Position: Q1 2026 in Review

RhumbLine Advisers held its Scinai Immunotherapeutics (SCNI) position steady in Q1 2026 at 1,878 shares worth $1.04K. The position accounts for ﹤0.01% of the portfolio, ranked #3975.

RhumbLine Advisers first reported a position in SCNI in Q2 2023 and has held it in 12 quarters since. The position peaked at $7.97K in Q2 2025. 4 funds tracked by Wall St. Rank hold SCNI as of Q1 2026.

  • RhumbLine Advisers held 1,878 shares of Scinai Immunotherapeutics worth $1.04K as of Q1 2026.
  • RhumbLine Advisers left its Scinai Immunotherapeutics share count unchanged in Q1 2026.
  • Scinai Immunotherapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3975 holding.
  • RhumbLine Advisers first reported a position in Scinai Immunotherapeutics in Q2 2023 and has held it in 12 quarters since.
  • RhumbLine Advisers's Scinai Immunotherapeutics position peaked at $7.97K in Q2 2025.
  • 4 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.